{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["IL-10", "Withania somnifera", "peritoneal mouse macrophages", "visceral leishmaniasis", "withaferin-A"]], "SpaceFlightMission": [], "InvestigatorList": [], "OtherAbstract": [], "OtherID": [], "CitationSubset": [], "GeneralNote": [], "PMID": "28553635", "DateRevised": {"Year": "2020", "Month": "09", "Day": "29"}, "Article": {"ArticleDate": [{"Year": "2017", "Month": "05", "Day": "12"}], "Language": ["eng"], "ELocationID": ["55", "10.3389/fmed.2017.00055"], "Journal": {"ISSN": "2296-858X", "JournalIssue": {"Volume": "4", "PubDate": {"Year": "2017"}}, "Title": "Frontiers in medicine", "ISOAbbreviation": "Front Med (Lausanne)"}, "ArticleTitle": "Alcoholic Fractions F5 and F6 from <i>Withania somnifera</i> Leaves Show a Potent Antileishmanial and Immunomodulatory Activities to Control Experimental Visceral Leishmaniasis.", "Pagination": {"StartPage": "55", "MedlinePgn": "55"}, "Abstract": {"AbstractText": ["Visceral leishmaniasis (VL) causes fatal life-threatening disease, if left untreated. The current drugs have various limitations; hence, natural products from medicinal plants are being focused in search of new drugs to treat leishmaniasis. The aim of the present study was to evaluate the antileishmanial and immunomodulatory activities of F5 and F6 alcoholic fractions from <i>Withania somnifera</i> leaves and purified withaferin-A in <i>Leishmania donovani</i>-infected peritoneal macrophages and BALB/c mice. We observed that F5 (15\u2009\u00b5g/mL), F6 (10\u2009\u00b5g/mL), and withaferin-A (1.5\u2009\u00b5M) reduce amastigote count in peritoneal macrophages and induce reactive oxygen species and significant decrease in IL-10 mRNA expression compared to control upon treatment. Subsequently, <i>in vivo</i> study mice were treated with F5 (25 and 50\u2009mg/kg b.wt.), F6 (25 and 50\u2009mg/kg b.wt.) orally, and withaferin-A (2\u2009mg/kg b.wt.) intraperitoneally for 10 consecutive days and a drastic reduction in parasite burden in both spleen and liver were observed. The treatment resulted in the reduction in IL-10, IL-4, and TGF-\u03b2 mRNA expression and a significant increase in IFN-\u03b3/IL-10 expression ratio in the treated group compared to control. The humoral response of these alcoholic fractions and withaferin-A shows increased IgG2a levels when compared with IgG1 in treated mice. Taken together, our result concludes that withanolides in alcoholic fractions demonstrate a potent antileishmanial and immunomodulatory activities in experimental VL."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Animal Biology, University of Hyderabad, Hyderabad, India."}], "LastName": "Chandrasekaran", "ForeName": "Sambamurthy", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Animal Biology, University of Hyderabad, Hyderabad, India."}], "LastName": "Veronica", "ForeName": "Jalaja", "Initials": "J"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Infectious Disease Research Laboratory, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India."}], "LastName": "Sundar", "ForeName": "Shyam", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Animal Biology, University of Hyderabad, Hyderabad, India."}], "LastName": "Maurya", "ForeName": "Radheshyam", "Initials": "R"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Front Med (Lausanne)", "NlmUniqueID": "101648047", "ISSNLinking": "2296-858X"}}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Paletta-Silva R, Meyer-Fernandes JR. Adenosine and immune imbalance in visceral leishmaniasis: the possible role of ectonucleotidases. J Trop Med (2012) 2012:650874.10.1155/2012/650874", "ArticleIdList": ["10.1155/2012/650874", "PMC3189589", "22007242"]}, {"Citation": "Alvar J, Velez ID, Bern C, Herrero M, Desjeux P, Cano J, et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS One (2012) 7:e35671.10.1371/journal.pone.0035671", "ArticleIdList": ["10.1371/journal.pone.0035671", "PMC3365071", "22693548"]}, {"Citation": "Banerjee A, De M, Ali N. Complete cure of experimental visceral leishmaniasis with amphotericin B in stearylamine-bearing cationic liposomes involves down-regulation of IL-10 and favorable T cell responses. J Immunol (2008) 181:1386\u201398.10.4049/jimmunol.181.2.1386", "ArticleIdList": ["10.4049/jimmunol.181.2.1386", "18606693"]}, {"Citation": "World Health Organization. Magnitude of the Problem. (2005). Available from: http://www.who.int/leishmaniasis/burden/magnitude/burden_magnitude/en/index.html"}, {"Citation": "Nwaka S, Ridley RG. Virtual drug discovery and development for neglected diseases through public-private partnerships. Nat Rev Drug Discov (2003) 2:919\u201328.10.1038/nrd1230", "ArticleIdList": ["10.1038/nrd1230", "14668812"]}, {"Citation": "Croft SL, Sundar S, Fairlamb AH. Drug resistance in leishmaniasis. Clin Microbiol Rev (2006) 19:111\u201326.10.1128/CMR.19.1.111-126.2006", "ArticleIdList": ["10.1128/CMR.19.1.111-126.2006", "PMC1360270", "16418526"]}, {"Citation": "Sundar S, Jha TK, Thakur CP, Sinha PK, Bhattacharya SK. Injectable paromomycin for visceral leishmaniasis in India. N Engl J Med (2007) 356:2571\u201381.10.1056/NEJMoa066536", "ArticleIdList": ["10.1056/NEJMoa066536", "17582067"]}, {"Citation": "Murray HW, Berman JD, Davies CR, Saravia NG. Advances in leishmaniasis. Lancet (2005) 366:1561\u201377.10.1016/S0140-6736(05)67629-5", "ArticleIdList": ["10.1016/S0140-6736(05)67629-5", "16257344"]}, {"Citation": "Belkaid Y, Hoffmann KF, Mendez S, Kamhawi S, Udey MC, Wynn TA, et al. The role of interleukin (IL)-10 in the persistence of Leishmania major in the skin after healing and the therapeutic potential of anti-IL-10 receptor antibody for sterile cure. J Exp Med (2001) 194:1497\u2013506.10.1084/jem.194.10.1497", "ArticleIdList": ["10.1084/jem.194.10.1497", "PMC2193677", "11714756"]}, {"Citation": "Binker MG, Zhao DY, Pang SJ, Harrison RE. Cytoplasmic linker protein-170 enhances spreading and phagocytosis in activated macrophages by stabilizing microtubules. J Immunol (2007) 179:3780\u201391.10.4049/jimmunol.179.6.3780", "ArticleIdList": ["10.4049/jimmunol.179.6.3780", "17785815"]}, {"Citation": "Van Wyk BE, Wink M. Medicinal Plants of the World. An Illustrated Scientific Guide to World Health Organization (WHO). Working to Overcome the Global Impact of Neglected Tropical Diseases: First WHO Report on Neglected Tropical Diseases. Geneva, Switzerland: WHO; (2010). 1 p."}, {"Citation": "Bhattacharya A, Ghosal S, Bhattacharya SK. Anti-oxidant effect of Withania somnifera glycowithanolides in chronic footshock stress-induced perturbations of oxidative free radical scavenging enzymes and lipid peroxidation in rat frontal cortex and striatum. J Ethnopharmacol (2001) 74:1\u20136.10.1016/S0378-8741(00)00309-3", "ArticleIdList": ["10.1016/S0378-8741(00)00309-3", "11137343"]}, {"Citation": "Dhuley JN. Adaptogenic and cardioprotective action of ashwagandha in rats and frogs. J Ethnopharmacol (2000) 70:57\u201363.10.1016/S0378-8741(99)00177-4", "ArticleIdList": ["10.1016/S0378-8741(99)00177-4", "10720789"]}, {"Citation": "Agarwal R, Diwanay S, Patki P, Patwardhan B. Studies on immunomodulatory activity of Withania somnifera (Ashwagandha) extracts in experimental immune inflammation. J Ethnopharmacol (1999) 67:27\u201335.10.1016/S0378-8741(99)00065-3", "ArticleIdList": ["10.1016/S0378-8741(99)00065-3", "10616957"]}, {"Citation": "Mondal S, Mandal C, Sangwan R, Chandra S, Mandal C. Withanolide D induces apoptosis in leukemia by targeting the activation of neutral sphingomyelinase-ceramide cascade mediated by synergistic activation of c-Jun N-terminal kinase and p38 mitogen-activated protein kinase. Mol Cancer (2010) 9:239.10.1186/1476-4598-9-239", "ArticleIdList": ["10.1186/1476-4598-9-239", "PMC2949798", "20836852"]}, {"Citation": "Harikrishnan B, Subramanian P, Subash S. Effect of Withania somnifera root powder on the levels of circulatory lipid peroxidation and liver marker enzymes in chronic hyperammonemia. E J Chem (2008) 5:872\u20137.10.1155/2008/589394", "ArticleIdList": ["10.1155/2008/589394"]}, {"Citation": "Kushwaha S, Roy S, Maity R, Mallick A, Soni VK, Singh PK, et al. Chemotypical variations in Withania somnifera lead to differentially modulated immune response in BALB/c mice. Vaccine (2012) 30:1083\u201393.10.1016/j.vaccine.2011.12.031", "ArticleIdList": ["10.1016/j.vaccine.2011.12.031", "22182427"]}, {"Citation": "Kushwaha S, Soni VK, Singh PK, Bano N, Kumar A, Sangwan RS, et al. Withania somnifera chemotypes NMITLI 101R, NMITLI 118R, NMITLI 128R and withaferin A protect Mastomys coucha from Brugia malayi infection. Parasite Immunol (2012) 34:199\u2013209.10.1111/j.1365-3024.2012.01352.x", "ArticleIdList": ["10.1111/j.1365-3024.2012.01352.x", "22394222"]}, {"Citation": "Lavie D, Kirson I, Abraham A. Steroidal lactones of W. somnifera. Harokaech Haivri (1972) 14(6):362\u20138."}, {"Citation": "Aggarwal R, Diwanay S, Patki P, Patwardhan B. Studies on immunomodulatory activity of Withania somnifera (Ashwagandha) extracts in experimental immune inflammation. J Ethnopharmacol (1999) 67(1):27\u201335.", "ArticleIdList": ["10616957"]}, {"Citation": "Sharma U, Velpandian T, Sharma P, Singh S. Evaluation of anti-leishmanial activity of selected Indian plants known to have antimicrobial properties. Parasitol Res (2009) 105(5):1287\u201393.10.1007/s00436-009-1554-2", "ArticleIdList": ["10.1007/s00436-009-1554-2", "19593584"]}, {"Citation": "Sen N, Banerjee B, Das BB, Ganguly A, Sen T, Pramanik S, et al. Apoptosis is induced in leishmanial cells by a novel protein kinase inhibitor withaferin A and is facilitated by apoptotic topoisomerase I-DNA complex. Cell Death Differ (2007) 14(2):358\u201367.10.1038/sj.cdd.4402002", "ArticleIdList": ["10.1038/sj.cdd.4402002", "16841091"]}, {"Citation": "Grover A, Katiyar SP, Jeyakanthan J, Dubey VK, Sundar D. Blocking protein kinase C signaling pathway: mechanistic insights into the anti-leishmanial activity of prospective herbal drugs from Withania somnifera. BMC Genomics (2012) 13(Suppl 7):S20.10.1186/1471-2164-13-S7-S20", "ArticleIdList": ["10.1186/1471-2164-13-S7-S20", "PMC3521472", "23281834"]}, {"Citation": "Kaur S, Chauhan K, Sachdeva H. Protection against experimental visceral leishmaniasis by immunostimulation with herbal drugs derived from Withania somnifera and Asparagus racemosus. J Med Microbiol (2014) 63(Pt 10):1328\u201338.10.1099/jmm.0.072694-0", "ArticleIdList": ["10.1099/jmm.0.072694-0", "25082945"]}, {"Citation": "Chandrasekaran S, Dayakar A, Veronica J, Sundar S, Maurya R. An in vitro study of apoptotic like death in Leishmania donovani promastigotes by withanolides. Parasitol Int (2013) 62:253\u201361.10.1016/j.parint.2013.01.007", "ArticleIdList": ["10.1016/j.parint.2013.01.007", "23416156"]}, {"Citation": "Chandrasekaran S, Veronica J, Gundampati RK, Sundar S, Maurya R. Exploring the inhibitory activity of Withaferin-A against pteridine reductase-1 of L. donovani. J Enzyme Inhib Med Chem (2016) 31(6):1029\u201337.10.3109/14756366.2015.1088841", "ArticleIdList": ["10.3109/14756366.2015.1088841", "26406482"]}, {"Citation": "Cohn ZA. Activation of mononuclear phagocytes: fact, fancy, and future. J Immunol (1978) 121:813\u20136.", "ArticleIdList": ["357655"]}, {"Citation": "Karnovsky ML, Lazdins JK. Biochemical criteria for activated macrophages. J Immunol (1978) 121:809\u201313.", "ArticleIdList": ["357654"]}, {"Citation": "Gomes A, Fernandes E, Lima JLFC. Fluorescence probes used for detection of reactive oxygen species. J Biochem Biophys Methods (2005) 65:45\u201380.10.1016/j.jbbm.2005.10.003", "ArticleIdList": ["10.1016/j.jbbm.2005.10.003", "16297980"]}, {"Citation": "Khan S, Malik F, Suri KA, Singh L. Molecular insight into the immune up-regulatory properties of the leaf extract of ashwagandha and identification of Th1 immunostimulatory chemical entity. Vaccine (2009) 27(43):6080\u20137.10.1016/j.vaccine.2009.07.011", "ArticleIdList": ["10.1016/j.vaccine.2009.07.011", "19628058"]}, {"Citation": "Bradley DJ, Kirkley J. Regulation of Leishmania populations within the host. I. The variable course of Leishmania donovani infections in mice. Clin Exp Immunol (1977) 30:119\u201329.", "ArticleIdList": ["PMC1541173", "606433"]}, {"Citation": "Koch A, Tamezb P, Pezzuto J, Soejarto D. Evaluation of plants used for antimalarial treatment by the Maasai of Kenya. J Ethnopharmacol (2005) 101(1\u20133):95\u20139.10.1016/j.jep.2005.03.011", "ArticleIdList": ["10.1016/j.jep.2005.03.011", "15878245"]}, {"Citation": "Patel SB, Rao NJ, Hingorani LL. Safety assessment of Withania somnifera extract standardized for Withaferin A: acute and sub-acute toxicity study. J Ayurveda Integr Med (2016) 7:30\u20137.10.1016/j.jaim.2015.08.001", "ArticleIdList": ["10.1016/j.jaim.2015.08.001", "PMC4910650", "27297507"]}, {"Citation": "Gantt KR, Goldman TL, Mccormick ML, Miller MA, Jeronimo SM, Nascimento ET, et al. Oxidative responses of human and murine macrophages during phagocytosis of Leishmania chagasi. J Immunol (2001) 167:893\u2013901.10.4049/jimmunol.167.2.893", "ArticleIdList": ["10.4049/jimmunol.167.2.893", "11441096"]}, {"Citation": "Seder RA, Gazzinelli R, Sher A, Paul WE. Interleukin-12 acts directly on CD4+ T-cells to enhance priming for interferon-gamma production and diminishes interleukin-4 inhibition of such priming. PNAS (1993) 90:10188\u201392.10.1073/pnas.90.21.10188", "ArticleIdList": ["10.1073/pnas.90.21.10188", "PMC47739", "7901851"]}, {"Citation": "Redhu NS, Dey A, Balooni V, Singh S. Leishmania-HIV co-infection: an emerging problem in India. AIDS (2006) 20:1213\u20135.10.1097/01.aids.0000226971.42622.4e", "ArticleIdList": ["10.1097/01.aids.0000226971.42622.4e", "16691082"]}, {"Citation": "Patricia S, Samanta PA, Marcia SCM, Frederico OP, Andre GT. Isolation of anti-leishmanial sterol from the fruits of Cassia fistula using bioguided fractionation. Phytother Res (2007) 21:644\u20137.10.1002/ptr.2131", "ArticleIdList": ["10.1002/ptr.2131", "17397117"]}, {"Citation": "Salem ML. Immunomodulatory and therapeutic properties of the Nigella sativa L. seed. Int Immunopharmacol (2005) 5:1749\u201370.10.1016/j.intimp.2005.06.008", "ArticleIdList": ["10.1016/j.intimp.2005.06.008", "16275613"]}, {"Citation": "Fulzele SV. Study of immunomodulatory activity of Haridradi ghrita in rats. Indian J Pharmacol (2003) 35:51\u20134."}, {"Citation": "Berger BJ, Fairlamb AH. Interactions between immunity and chemotherapy in the treatment of the trypanosomiases and leishmaniases. Parasitology (1992) 105:S71\u20138.10.1017/S0031182000075375", "ArticleIdList": ["10.1017/S0031182000075375", "1308932"]}, {"Citation": "Owais M, Sharad KS, Shehbaz A, Saleemuddin M. Antibacterial efficacy of Withania somnifera (Ashwagandha) an indigenous medicinal plant against experimental murine salmonellosis. Phytomedicine (2005) 12:229\u201335.10.1016/j.phymed.2003.07.012", "ArticleIdList": ["10.1016/j.phymed.2003.07.012", "15830846"]}, {"Citation": "Ghosh M. Purification of a lectin-like antifungal protein from the medicinal herb, Withania somnifera. Fitoterapia (2009) 80:91\u20135.10.1016/j.fitote.2008.10.004", "ArticleIdList": ["10.1016/j.fitote.2008.10.004", "18977281"]}, {"Citation": "Tripathi CDP, Gupta R, Kushawaha PK, Mandal C, Bhattacharya SM, Dube A. Efficacy of Withania somnifera chemotypes NMITLI-101R, 118R and Withaferin A against experimental visceral leishmaniasis. Parasite Immunol (2014) 36:253\u201365.10.1111/pim.12112", "ArticleIdList": ["10.1111/pim.12112", "24830833"]}, {"Citation": "Melby PC, Chandrasekar B, Zhao WG, Coe JE. The hamster as a model of human visceral leishmaniasis: progressive disease and impaired generation of nitric oxide in the face of a prominent Th1-like cytokine response. J Immunol (2001) 166:1912\u201320.10.4049/jimmunol.166.3.1912", "ArticleIdList": ["10.4049/jimmunol.166.3.1912", "11160239"]}, {"Citation": "Shah V, Bayeta E, Lau BHS. Pycnogenol augments macrophage phagocytosis and cytokine secretion. Pak J Nutr (2002) 1:196\u2013201.10.3923/pjn.2002.196.201", "ArticleIdList": ["10.3923/pjn.2002.196.201"]}, {"Citation": "Liew FY. Role of cytokines in killing of intracellular pathogens. Immunol Lett (1991) 30:193\u20138.10.1016/0165-2478(91)90024-5", "ArticleIdList": ["10.1016/0165-2478(91)90024-5", "1757104"]}, {"Citation": "Assreuy J, Cunha FQ, Epperlein M, Noronha-Dutra A, O\u2019Donnell CA, Liew FY, et al. Production of nitric oxide and superoxide by activated macrophages and killing of Leishmania major. Eur J Immunol (1994) 24:672\u20136.10.1002/eji.1830240328", "ArticleIdList": ["10.1002/eji.1830240328", "8125136"]}, {"Citation": "Liew FY, Li Y, Millott S. Tumor-necrosis-factor (TNF-alpha) in Leishmaniasis TNF-alpha-induced macrophage leishmanicidal activity is mediated by nitric-oxide from l-arginine. Immunology (1990) 71:556\u20139.", "ArticleIdList": ["PMC1384878", "2279740"]}, {"Citation": "Stenger S, Donhauser N, Thuring H, R\u00f6llinghoff M, Bogdan C. Reactivation of latent leishmaniasis by inhibition of inducible nitric oxide synthase. J Exp Med (1996) 183:1501\u201314.10.1084/jem.183.4.1501", "ArticleIdList": ["10.1084/jem.183.4.1501", "PMC2192515", "8666908"]}, {"Citation": "Basak SK, Saha B, Bhattacharya A, Roy S. Immunobiological studies on experimental visceral leishmaniasis. II. Adherent cell-mediated down-regulation of delayed-type hypersensitivity response and up-regulation of B cell activation. Eur J Immunol (1992) 22:2041\u20135.10.1002/eji.1830220813", "ArticleIdList": ["10.1002/eji.1830220813", "1386313"]}, {"Citation": "Kaye PM, Curry AJ, Blackwell JM. Differential production of Th1- and Th2-derived cytokines does not determine the genetically controlled or vaccine-induced rate of cure in murine visceral leishmaniasis. J Immunol (1991) 146:2763\u201370.", "ArticleIdList": ["1901883"]}, {"Citation": "Ghalib HW, Piuvezam MR, Skeiky YA, Siddig M, Hashim FA, El-Hassan AM, et al. Interleukin 10 production correlates with pathology in human Leishmania donovani infections. J Clin Invest (1993) 92:324\u20139.10.1172/JCI116570", "ArticleIdList": ["10.1172/JCI116570", "PMC293600", "8326000"]}, {"Citation": "Karp CL, El-Safi SH, Wynn TA, Satti MM, Kordofani AM, Hashim FA, et al. In vivo cytokine profiles in patients with kala-azar. Marked elevation of both interleukin-10 and interferon-gamma. J Clin Invest (1993) 91:1644\u20138.10.1172/JCI116372", "ArticleIdList": ["10.1172/JCI116372", "PMC288142", "8097208"]}, {"Citation": "Mukhopadhyay D, Das NK, Roy S, Kundu SJN, Barbhuiya JN, Chatterjee M. Miltefosine effectively modulates the cytokine milieu in Indian post kala-azar dermal leishmaniasis. J Infect Dis (2011) (9):1427\u201336.10.1093/infdis/jir551", "ArticleIdList": ["10.1093/infdis/jir551", "21933878"]}, {"Citation": "Gautam S, Kumar R, Maurya R, Nyl\u00e9n S, Ansari N, Rai M, et al. IL-10 neutralization promotes parasite clearance in splenic aspirate cells from patients with visceral leishmaniasis. J Infect Dis (2011) 204(7):1134\u20137.10.1093/infdis/jir461", "ArticleIdList": ["10.1093/infdis/jir461", "PMC3164427", "21881130"]}, {"Citation": "Gidwani K, Jones S, Kumar R, Boelaert M, Sundar S. Interferon-gamma release assay (modified quantiferon) as a potential marker of infection for Leishmania donovani, a proof of concept study. PLoS Negl Trop Dis (2011) 5:e1042.10.1371/journal.pntd.0001042", "ArticleIdList": ["10.1371/journal.pntd.0001042", "PMC3079582", "21526219"]}, {"Citation": "Kumar R, Singh N, Gautam S, Singh OP, Gidwani K, Rai M, et al. Leishmania specific CD4 T cells release IFN\u03b3 that limits parasite replication in patients with visceral leishmaniasis. PLoS Negl Trop Dis (2014) 8(10):e3198.10.1371/journal.pntd.0003198", "ArticleIdList": ["10.1371/journal.pntd.0003198", "PMC4183461", "25275531"]}, {"Citation": "Paul J, Karmakar S, De T. TLR-mediated distinct IFN-gamma/IL-10 pattern induces protective immunity against murine visceral leishmaniasis. Eur J Immunol (2012) 42:2087\u201399.10.1002/eji.201242428", "ArticleIdList": ["10.1002/eji.201242428", "22622993"]}, {"Citation": "Buxbaum LU. A detrimental role for IgG and FcgammaR in Leishmania mexicana infection. Immunol Res (2008) 42:197\u2013209.10.1007/s12026-008-8074-5", "ArticleIdList": ["10.1007/s12026-008-8074-5", "19002608"]}, {"Citation": "Baker RCP, Kaye PM. Leishmaniasis. In: Zumla DGJA, editor. The Granulomatous Disorders. Cambridge, UK: Cambridge University Press; (1999). p. 212\u201334."}]}], "History": [{"Year": "2017", "Month": "2", "Day": "8"}, {"Year": "2017", "Month": "4", "Day": "24"}, {"Year": "2017", "Month": "5", "Day": "30", "Hour": "6", "Minute": "0"}, {"Year": "2017", "Month": "5", "Day": "30", "Hour": "6", "Minute": "0"}, {"Year": "2017", "Month": "5", "Day": "30", "Hour": "6", "Minute": "1"}, {"Year": "2017", "Month": "5", "Day": "12"}], "PublicationStatus": "epublish", "ArticleIdList": ["28553635", "PMC5427131", "10.3389/fmed.2017.00055"]}}]}